A

Aspen Neuroscience, Inc.

ASPEPriced

Aspen Neuroscience, Inc. · Nasdaq Global Select Market · Research source · S-1 · 2026-10-09 · Latest filing · 8-K · 2026-11-02 SEC ↗

Report source
Research source · S-1 · 2026-10-09
SummaryBASIC RESEARCHReport source · S-1

Aspen’s preliminary IPO terms remain materially incomplete, with no price, size, proceeds or effective listing disclosed.

As of the October 9, 2026 S-1, Aspen proposed an IPO of common stock but left key pricing and share figures blank.

Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointSEC effectiveness and final pricing are not supplied; no confirmed closing or trading date is disclosed.S-1 · 2026-10-09
Business and development direction

Aspen Neuroscience, Inc.

Current business
Future development
DECISION DRIVERS

Key risks

Risk 1

The company has limited operating history, no commercialization history and substantial accumulated losses, with going-concern doubt.

Risk 2

Failure or delay in sasineprocel development, regulatory approval or commercialization would materially harm the business because it is the lead product candidate.

Risk 3

Autologous manufacturing involves variability and the novel process may cause manufacturing failures, treatment delays or inconsistent quality.

Next checkSEC effectiveness and final pricing are not supplied; no confirmed closing or trading date is disclosed.
Latest filing2026-11-02
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualitySource-linked structured inputs are not yet available. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
PRELIMINARY
#InstitutionUnderwriting allocationRatioShares
1Leerink Partners LLC
2Piper Sandler & Co.
3Stifel, Nicolaus & Company, Incorporated
4UBS Securities LLC
5Oppenheimer & Co. Inc.
Source and calculation

Names are explicitly identified in source underwriting tables or role clauses. Quantities require the named firm's own table row; missing allocations are not inferred.

Source · S-1 ↗

IPO CAPITAL QUALITY

Issuer capital
Selling-holder liquidity
Primary shares
Secondary shares
Basis and evidence

S-1 · 2026-10-09

As of the October 9, 2026 S-1, Aspen proposed an IPO of common stock but left key pricing and share figures blank.

Offering structure

Source and calculation
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Use of proceedsSource-linked structured inputs are not yet available. Open filing ↗

Dilution and valuation

IPO price—
Basic post-offer—
Equity value—

Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.

Dilution and valuation
CalculationSharesValueReference
Pre-offer shares · Aspen Neuroscience, Inc.188,558,695—
Reported sourceAspen Neuroscience, Inc.sharesBasis and evidence 1 ↗
Basis and evidence ↗
Basis and evidence 1

As of June 30, 2026, after assumed preferred-stock conversion; offering basis

Reported inputs; each row retains its own source basis.

The Offering ↗

Share-count comparison

Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Source inputs required

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Source ↗
Implied equity value—Price × post-offer shares
Post-offer shares—Share count, not tradable float
Existing-holder ownership reduction—Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Base post-offer shares

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Equity value

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Share-count change

Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.

Alternative scenarios

Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.

Sensitivity

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesSome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
As of
2026-10-09
!The supplied evidence shows a large post-conversion share base and potential concentrated control, but omits complete percentages and voting rights.View source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Aspen Neuroscience, Inc.
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
Entities affiliated with OrbiMed Private Investments VII, LPBeneficial shares25,586,039——
Number of Shares; Beneficially OwnedDisclosedEvidence
Entities affiliated with Gilead Sciences, Inc.Beneficial shares16,470,124——
Number of Shares; Beneficially OwnedDisclosedEvidence
Entities affiliated with Frazier Life Sciences X, L.P.Beneficial shares13,251,770——
Number of Shares; Beneficially OwnedDisclosedEvidence
Entities affiliated with Q Healthcare Holding LLCBeneficial shares13,176,099——
Number of Shares; Beneficially OwnedDisclosedEvidence
Entities affiliated with ARCH Venture Fund X, L.P.Beneficial shares23,930,336——
Number of Shares; Beneficially OwnedDisclosedEvidence
Entities affiliated with Abu Dhabi Investment AuthorityBeneficial shares12,816,358——
Number of Shares; Beneficially OwnedDisclosedEvidence
Entities affiliated with Medical Excellence Capital Partners, LPBeneficial shares10,658,060——
Number of Shares; Beneficially OwnedDisclosedEvidence
Damien McDevittBeneficial shares8,254,091——
Number of Shares; Beneficially OwnedDisclosedEvidence
Dalen MeeterBeneficial shares709,270——
Number of Shares; Beneficially OwnedDisclosedEvidence
Kim RaineriBeneficial shares1,114,583——
Number of Shares; Beneficially OwnedDisclosedEvidence
Faheem HasnainBeneficial shares1,249,982——
Number of Shares; Beneficially OwnedDisclosedEvidence
Thomas Daniel, M.D.Beneficial shares1,117,478——
Number of Shares; Beneficially OwnedDisclosedEvidence
Entities affiliated with OrbiMed Private Investments VII, LPBeneficial ownership—13.1%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Entities affiliated with Gilead Sciences, Inc.Beneficial ownership—8.4%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Entities affiliated with Frazier Life Sciences X, L.P.Beneficial ownership—6.8%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Entities affiliated with Q Healthcare Holding LLCBeneficial ownership—6.8%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Entities affiliated with ARCH Venture Fund X, L.P.Beneficial ownership—12.3%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Entities affiliated with Abu Dhabi Investment AuthorityBeneficial ownership—6.6%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Entities affiliated with Medical Excellence Capital Partners, LPBeneficial ownership—5.5%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Damien McDevittBeneficial ownership—4.2%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Andrew SpaventaBeneficial ownership—1.9%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Peter A. Thompson, M.D.Beneficial ownership—13.1%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
All executive officers and directors as a group (12 persons)Beneficial ownership—21.2%Beneficial—
Percentage of Shares Beneficially Owned; Before OfferingDisclosedEvidence
Caryn PetersonBeneficial shares410,473——
Number of Shares; Beneficially OwnedDisclosedEvidence
Andrew SpaventaBeneficial shares3,777,944——
Number of Shares; Beneficially OwnedDisclosedEvidence
Peter A. Thompson, M.D.Beneficial shares25,586,039——
Number of Shares; Beneficially OwnedDisclosedEvidence
All executive officers and directors as a group (12 persons)Beneficial shares42,852,151——
Number of Shares; Beneficially OwnedDisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller findingDisclosedEvidence
Source and calculation ↗
Entities affiliated with OrbiMed Private Investments VII, LP · Entities affiliated with OrbiMed Private Investments VII, LP — Beneficial shares · 25,586,039

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with OrbiMed Private Investments VII, LP(1)

0001193125-26-419104 · SEC table 28 row 5 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Entities affiliated with Gilead Sciences, Inc. · Entities affiliated with Gilead Sciences, Inc. — Beneficial shares · 16,470,124

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Gilead Sciences, Inc. (2)

0001193125-26-419104 · SEC table 28 row 6 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Entities affiliated with Frazier Life Sciences X, L.P. · Entities affiliated with Frazier Life Sciences X, L.P. — Beneficial shares · 13,251,770

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Frazier Life Sciences X, L.P. (3)

0001193125-26-419104 · SEC table 28 row 7 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Entities affiliated with Q Healthcare Holding LLC · Entities affiliated with Q Healthcare Holding LLC — Beneficial shares · 13,176,099

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Q Healthcare Holding LLC (4)

0001193125-26-419104 · SEC table 28 row 8 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Entities affiliated with ARCH Venture Fund X, L.P. · Entities affiliated with ARCH Venture Fund X, L.P. — Beneficial shares · 23,930,336

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with ARCH Venture Fund X, L.P.(5)

0001193125-26-419104 · SEC table 28 row 9 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Entities affiliated with Abu Dhabi Investment Authority · Entities affiliated with Abu Dhabi Investment Authority — Beneficial shares · 12,816,358

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Abu Dhabi Investment Authority (6)

0001193125-26-419104 · SEC table 28 row 10 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Entities affiliated with Medical Excellence Capital Partners, LP · Entities affiliated with Medical Excellence Capital Partners, LP — Beneficial shares · 10,658,060

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Entities affiliated with Medical Excellence Capital Partners, LP (7)

0001193125-26-419104 · SEC table 28 row 11 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Damien McDevitt · Damien McDevitt — Beneficial shares · 8,254,091

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Damien McDevitt (8)

0001193125-26-419104 · SEC table 28 row 14 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Dalen Meeter · Dalen Meeter — Beneficial shares · 709,270

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Dalen Meeter (9)

0001193125-26-419104 · SEC table 28 row 15 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Kim Raineri · Kim Raineri — Beneficial shares · 1,114,583

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Kim Raineri (10)

0001193125-26-419104 · SEC table 28 row 16 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Faheem Hasnain · Faheem Hasnain — Beneficial shares · 1,249,982

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Faheem Hasnain (11)

0001193125-26-419104 · SEC table 28 row 17 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Thomas Daniel, M.D. · Thomas Daniel, M.D. — Beneficial shares · 1,117,478

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Thomas Daniel, M.D.(12)

0001193125-26-419104 · SEC table 28 row 18 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Entities affiliated with OrbiMed Private Investments VII, LP · Entities affiliated with OrbiMed Private Investments VII, LP — Beneficial ownership · 13.1%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with OrbiMed Private Investments VII, LP(1)

0001193125-26-419104 · SEC table 28 row 5 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Entities affiliated with Gilead Sciences, Inc. · Entities affiliated with Gilead Sciences, Inc. — Beneficial ownership · 8.4%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Gilead Sciences, Inc. (2)

0001193125-26-419104 · SEC table 28 row 6 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Entities affiliated with Frazier Life Sciences X, L.P. · Entities affiliated with Frazier Life Sciences X, L.P. — Beneficial ownership · 6.8%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Frazier Life Sciences X, L.P. (3)

0001193125-26-419104 · SEC table 28 row 7 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Entities affiliated with Q Healthcare Holding LLC · Entities affiliated with Q Healthcare Holding LLC — Beneficial ownership · 6.8%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Q Healthcare Holding LLC (4)

0001193125-26-419104 · SEC table 28 row 8 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Entities affiliated with ARCH Venture Fund X, L.P. · Entities affiliated with ARCH Venture Fund X, L.P. — Beneficial ownership · 12.3%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with ARCH Venture Fund X, L.P.(5)

0001193125-26-419104 · SEC table 28 row 9 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Entities affiliated with Abu Dhabi Investment Authority · Entities affiliated with Abu Dhabi Investment Authority — Beneficial ownership · 6.6%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Abu Dhabi Investment Authority (6)

0001193125-26-419104 · SEC table 28 row 10 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Entities affiliated with Medical Excellence Capital Partners, LP · Entities affiliated with Medical Excellence Capital Partners, LP — Beneficial ownership · 5.5%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Entities affiliated with Medical Excellence Capital Partners, LP (7)

0001193125-26-419104 · SEC table 28 row 11 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Damien McDevitt · Damien McDevitt — Beneficial ownership · 4.2%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Damien McDevitt (8)

0001193125-26-419104 · SEC table 28 row 14 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Andrew Spaventa · Andrew Spaventa — Beneficial ownership · 1.9%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Andrew Spaventa (14)

0001193125-26-419104 · SEC table 28 row 22 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Peter A. Thompson, M.D. · Peter A. Thompson, M.D. — Beneficial ownership · 13.1%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: Peter A. Thompson, M.D. (15)

0001193125-26-419104 · SEC table 28 row 23 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

All executive officers and directors as a group (12 persons) · All executive officers and directors as a group (12 persons) — Beneficial ownership · 21.2%

Exact source ownership column: Percentage of Shares Beneficially Owned; Before Offering; holders may overlap; not an additive partition

Raw source column: Percentage of Shares Beneficially Owned; Before Offering; source holder: All executive officers and directors as a group (12 persons) (16)

0001193125-26-419104 · SEC table 28 row 24 columns 7; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:6,3:6 ↗

Caryn Peterson · Caryn Peterson — Beneficial shares · 410,473

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Caryn Peterson (13)

0001193125-26-419104 · SEC table 28 row 21 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Andrew Spaventa · Andrew Spaventa — Beneficial shares · 3,777,944

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Andrew Spaventa (14)

0001193125-26-419104 · SEC table 28 row 22 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

Peter A. Thompson, M.D. · Peter A. Thompson, M.D. — Beneficial shares · 25,586,039

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: Peter A. Thompson, M.D. (15)

0001193125-26-419104 · SEC table 28 row 23 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

All executive officers and directors as a group (12 persons) · All executive officers and directors as a group (12 persons) — Beneficial shares · 42,852,151

Exact source ownership column: Number of Shares; Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Number of Shares; Beneficially Owned; source holder: All executive officers and directors as a group (12 persons) (16)

0001193125-26-419104 · SEC table 28 row 24 columns 4; source 2968424:3057582; SHA256 342f6bc3a3f631a13aa855806670b6c7468d4dcf3dcb79cb88975ca3a05c2c48; ownership header cells 2:3,3:3 ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller finding

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter.

0001193125-26-419104 · SEC ownership paragraph; source 3088797:3089923; SHA256 fc3bc211fd283f1fd1f2e8033154ec83cab7e1deb82b4f6ad23f2e37e0b9847f ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
Our directors and executive officers and substantially all of our securityholdersAfter date of this prospectus · Source conditions apply180 days
We, our officers, directors, and substantially all of our securityholders,After date of this prospectus · Source conditions apply180 days
We, our executive officers and directors and substantially all of our other existing security holdersAfter date of this prospectus · Source conditions apply180 days
Source and calculation
Our directors and executive officers and substantially all of our securityholders

Our directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus &

SEC lock-up paragraph; source 1145445:1146332; SHA256 4c9c5a3d580c688c9836918f296b207506af64313e1abad0a00cccb778dce842 ↗
We, our officers, directors, and substantially all of our securityholders,

We, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC.

SEC lock-up paragraph; source 3161450:3162937; SHA256 3aec14628e47d0be7eddd7b9151b83fc82272dbeb0e04e91cc554779dce5316d ↗
We, our executive officers and directors and substantially all of our other existing security holders

We, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:

SEC lock-up paragraph; source 3275359:3276377; SHA256 3e965170460ce302569bc5d22176cf4329210d943f2f84f33dd880b7020d8f54 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

date of this prospectus

  1. Our directors and executive officers and substantially all of our securityholdersOur directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus &
  2. We, our officers, directors, and substantially all of our securityholders,We, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC.
  3. We, our executive officers and directors and substantially all of our other existing security holdersWe, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:
Holder / event
Holder / eventTerm / dateConditions
Our directors and executive officers and substantially all of our securityholders180 daysOur directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus &
We, our officers, directors, and substantially all of our securityholders,180 daysWe, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC.
We, our executive officers and directors and substantially all of our other existing security holders180 daysWe, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:
Basis and evidence
Our directors and executive officers and substantially all of our securityholders

Our directors and executive officers and substantially all of our securityholders have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions and among other things, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus &

SEC lock-up paragraph; source 1145445:1146332; SHA256 4c9c5a3d580c688c9836918f296b207506af64313e1abad0a00cccb778dce842 ↗
We, our officers, directors, and substantially all of our securityholders,

We, our officers, directors, and substantially all of our securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant for the sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock, or exercise any right with respect to the registration of any of such securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act, or enter into any swap or any other agreement or any transaction that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, without the prior written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC.

SEC lock-up paragraph; source 3161450:3162937; SHA256 3aec14628e47d0be7eddd7b9151b83fc82272dbeb0e04e91cc554779dce5316d ↗
We, our executive officers and directors and substantially all of our other existing security holders

We, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and UBS Securities LLC on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:

SEC lock-up paragraph; source 3275359:3276377; SHA256 3e965170460ce302569bc5d22176cf4329210d943f2f84f33dd880b7020d8f54 ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported
FY2024($48,557,000)
FY2025($62,056,000)

Operating cash flow

$ · Annual values as reported
FY2024($44,162,000)
FY2025($52,847,000)
Financial quality
CalculationFY2024FY2025
Net income / (loss)($48,557,000)($62,056,000)
Operating cash flow($44,162,000)($52,847,000)
Financial quality
CalculationReported value
Cash and cash equivalents2025-12-31$82,097,000
Cash and cash equivalents2024-12-31$15,221,000
Current assets2025-12-31$112,386,000
Current assets2024-12-31$59,590,000
Total assets2025-12-31$143,663,000
Total assets2024-12-31$90,211,000
Current liabilities2025-12-31$14,263,000
Current liabilities2024-12-31$14,038,000
Total equity / (deficit)2025-12-31($217,077,000)
Total equity / (deficit)2024-12-31($157,727,000)
General and administrative expensesFY2025$17,472,000
General and administrative expensesFY2024$17,865,000
Cash and cash equivalents2026-06-30 · Unaudited$21,287,000
Current assets2026-06-30 · Unaudited$74,595,000
Total assets2026-06-30 · Unaudited$110,275,000
Current liabilities2026-06-30 · Unaudited$16,352,000
Total equity / (deficit)2026-06-30 · Unaudited($251,073,000)
General and administrative expenses6M ended 2026-06-30 · Unaudited$9,764,000
General and administrative expenses6M ended 2025-06-30 · Unaudited$10,074,000
Net income / (loss)6M ended 2026-06-30 · Unaudited($36,546,000)
Net income / (loss)6M ended 2025-06-30 · Unaudited($31,759,000)
Operating cash flow6M ended 2026-06-30 · Unaudited($34,505,000)
Operating cash flow6M ended 2025-06-30 · Unaudited($30,619,000)
Basis and evidence
Cash and cash equivalents
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
General and administrative
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
General and administrative
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash used in operating activities
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Cash and cash equivalents
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current assets
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total assets
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total current liabilities
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
Total stockholders’ deficit
June 30, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-06-30
General and administrative
6M ended 2026-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2026-06-30
General and administrative
6M ended 2025-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2025-06-30
Net loss
6M ended 2026-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2026-06-30
Net loss
6M ended 2025-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2025-06-30
Net cash used in operating activities
6M ended 2026-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2026-06-30
Net cash used in operating activities
6M ended 2025-06-30; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 6 months ended 2025-06-30
Financial quality and runway
Financial review

Financial quality and runway

The latest supplied financial period is the unaudited six months ended June 30, 2026; the company reports losses, cash runway pressure and going-concern doubt.

Cash and cash equivalents$82,097,000
Cash and cash equivalents$15,221,000
Total current assets$112,386,000
EvidenceFinancial review 1

Six-month 2026 operating expenses were $38.218 million and net loss was $36.546 million, in thousands in the table.

EvidenceFinancial review 2

Cash, cash equivalents and marketable securities were $72.4 million as of June 30, 2026, while accumulated deficit was $264.9 million.

EvidenceFinancial review 3

Management concluded substantial doubt exists about continuing as a going concern because existing liquidity was not sufficient for the following 12 months from issuance of the unaudited financial statements.

EvidenceFinancial review 4

Revenue and debt amounts are not supplied in the excerpts.

LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open S-1 ↗

No source-comparable material changes identified in this report.

IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.

Loading filing history…

Risk 4

The open-label ASPIRO trial has no placebo or control cohort, limiting interpretation and predictive value of results.

DocumentS-10001193125-26-419104
Filed2026-10-09SEC EDGAR
Research updated2026-10-10Analysed
Source-bound table inputs54SEC EDGAR
Open filing ↗